Editor Profile

Helmut Albrecht, MD

Past Contributing Editor

About the NEJM Journal Watch Infectious Diseases Board

Helmut Albrecht, MD, is the Heyward Gibbes Distinguished Professor of Medicine and Chief of the Division of Infectious Diseases at the University of South Carolina School of Medicine. He has served as an investigator of multiple national and international trials, and has published several book chapters and more than 100 articles in peer-reviewed journals. He is a founding member and former president of KAAD (Klinische Arbeitsgemeinschaft AIDS Deutschland/German AIDS Clinical Trial Group). Dr. Albrecht served on the NEJM Journal Watch AIDS Clinical Care Editorial Board since 2004. He was a member of the NEJM Journal Watch Infectious Diseases Editorial Board from 2014 to 2016.


Grant / Research support

Health Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societies

Columbia Medical Society; South Carolina Infectious Diseases Society

  • February 11, 2013

    Lersivirine — A Promising New Nonnucleoside Reverse Transcriptase Inhibitor

    1. Helmut Albrecht, MD

    In a dose-finding study, efficacy and safety were similar between lersivirine (500 or 750 mg once daily) and efavirenz (600 mg once daily).

  • January 13, 2012

    Is HIV Becoming More Virulent?

    1. Helmut Albrecht, MD

    A meta-analysis suggests that over the course of the epidemic, the mean virologic set point of HIV-infected patients has been increasing and the mean baseline CD4-cell count has been decreasing.

  • September 24, 2012

    Tenofovir for Hepatitis B in HIV-Coinfected Patients

    1. Helmut Albrecht, MD

    Tenofovir therapy is associated with a significant decrease in hepatitis B surface antigen levels, but very few patients completely clear surface antigen, even with years of therapy.

  • January 30, 2012

    HIV Viral Loads — the Lower, the Better?Free

    1. Helmut Albrecht, MD

    Patients with low-level viremia on sensitive assays have an increased risk for virologic failure, but the optimal management of such patients remains unclear.

  • August 27, 2012

    Atazanavir-Induced Cholelithiasis

    1. Helmut Albrecht, MD

    Fourteen patients on atazanavir developed complicated cholelithiasis. Infrared spectrometry analysis of 11 stones from these patients revealed that 8 contained substantial levels of atazanavir.

  • May 7, 2012

    Dolutegravir Holds Promise

    1. Helmut Albrecht, MD

    In a 48-week, phase II study, this investigational integrase inhibitor was as effective as efavirenz and better tolerated.